TL;DR
Get everyday helpers delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
In interim results from the phase III ADAPT OCULUS trial, subcutaneous efgartigimod PH20 improved the primary patient-reported ocular symptom score at four weeks compared with placebo. A combined patient-report and physician-exam score also favored treatment, while the difference on a separate daily-activities measure was not statistically significant. The drug is not FDA-approved for ocular myasthenia gravis.
Subcutaneous efgartigimod PH20 improved a patient-reported ocular symptom score compared with placebo at four weeks in the phase III ADAPT OCULUS trial, meeting the study’s primary endpoint, interim results showed. The finding offers evidence for a targeted treatment under study for ocular myasthenia gravis, but the drug is not currently approved by the FDA for that condition.
Participants receiving efgartigimod had a mean 4.04-point improvement from baseline on the ocular score of the Myasthenia Impairment Index Patient Reported Outcome (MGII PRO). The placebo group improved by 1.99 points, a mean difference of 2.05 points (P=0.012), Vern Juel, MD, of Duke University School of Medicine reported at an American Association of Neuromuscular and Electrodiagnostic Medicine meeting.
A key secondary measure combining patient reports with physician examination also favored the drug: the mean improvement was 5.02 points with efgartigimod and 2.57 points with placebo, a 2.44-point difference (P=0.018). On the ocular domain of the Myasthenia Gravis Activities of Daily Living scale, results followed a similar numerical direction, but the difference was not statistically significant (P=0.60). Juel said the treatment improved double vision and drooping eyelids, symptoms associated with the condition.
The trial enrolled 141 people with ocular myasthenia gravis. In part A, participants received four weekly injections of 1,000 mg efgartigimod PH20 or placebo, then were followed for four weeks. The primary endpoint compared MGII PRO ocular scores at baseline and week four. In the open-label part B extension, participants received multiple treatment cycles; Juel reported score improvements across cycles in both anti-AChR antibody and triple-seronegative groups.
Evidence for Ocular Symptom Relief
Ocular myasthenia gravis can cause double vision and eyelid drooping, and its effects may extend beyond symptoms observed during an examination. The trial’s primary measure focused on what patients reported about ocular symptoms, while a second measure incorporated a physician examination. Improvement on both measures gives clinicians and researchers more information about how treatment may affect symptoms as experienced by patients.
The results remain interim clinical-trial evidence, not proof that the treatment is appropriate for every patient or that benefits will persist over time. The non-significant result on the MG-ADL ocular measure also shows that findings differed across outcome measures. The data may inform future regulatory and clinical discussions, but they do not change the drug’s current FDA status for ocular disease.
ocular myasthenia gravis eye drops
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
A Trial Focused on Ocular MG
Juel described ocular myasthenia gravis as historically understudied, with an unmet need for safe and effective targeted therapies. Efgartigimod is an antibody fragment that binds to the neonatal Fc receptor, reducing circulating IgG antibodies. The treatment has existing approvals for other conditions: intravenous efgartigimod was approved in 2021 for generalized myasthenia gravis in people with anti-AChR antibodies, and a subcutaneous formulation with hyaluronidase was approved in 2023. The source also reports a 2026 expansion of the generalized-disease indication.
ADAPT OCULUS included people with MGFA class I disease, any antibody serotype, and a baseline MGII PRO ocular score of at least six. Participants were on stable doses of background therapies such as acetylcholinesterase inhibitors, corticosteroids, or other immunosuppressive medicines. Of the 71 assigned to efgartigimod, 81.3% had anti-AChR antibodies and 16.9% were triple seronegative. Argenx, the drugmaker, described the trial as the first registrational study specifically evaluating a targeted treatment for ocular myasthenia gravis.
“Ocular myasthenia gravis has been understudied historically and there’s an unmet need for safe, effective, and targeted therapies.”
— Vern Juel, MD, of Duke University School of Medicine
eyelid drooping treatment for myasthenia gravis
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Approval and Longer-Term Benefit
The results provided do not establish whether the FDA will approve efgartigimod for ocular myasthenia gravis, or when a regulatory decision might occur. The drug is not currently approved for this indication. The source describes the findings as interim and does not provide a complete account of long-term efficacy, the full safety results by treatment group, or the final analysis.
Juel said adverse events were consistent with prior clinical studies and real-world evidence in generalized myasthenia gravis. There was one serious treatment-emergent adverse event in part A and 17 events across parts A and B combined. Headache, injection-site redness, and upper respiratory tract infections were the most commonly reported treatment-emergent events in both parts. The supplied report does not detail the nature or severity of each event, or provide enough information to judge risks for individual patients.
As an affiliate, we earn on qualifying purchases.
Further Trial and Regulatory Updates
Part B of ADAPT OCULUS is an open-label extension in which participants receive multiple treatment cycles. Further reporting may clarify whether symptom-score improvements are sustained across cycles and provide more detail on safety. The available source does not give a schedule for completion, publication of final results, or any regulatory filing for ocular myasthenia gravis.
Until additional results or an FDA decision are reported, the findings should be understood as evidence from a clinical trial, rather than a change in approved treatment options. Any treatment decisions for myasthenia gravis should be made with a qualified clinician familiar with the patient’s condition and medical history.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the ADAPT OCULUS trial find?
At four weeks, the efgartigimod group had a 4.04-point mean improvement in the MGII PRO ocular score, compared with 1.99 points with placebo. The 2.05-point difference met the study’s primary endpoint (P=0.012).
Was every symptom measure significantly better with treatment?
No. The combined MGII patient-report and physician-exam measure favored efgartigimod, but the difference on the MG-ADL ocular domain was not statistically significant (P=0.60).
Is efgartigimod approved for ocular myasthenia gravis?
No. The source says efgartigimod is not currently FDA-approved for ocular myasthenia gravis. The reported results are from a clinical trial.
What side effects were reported?
Headache, injection-site redness, and upper respiratory tract infections were the most common treatment-emergent events reported in the trial. The interim report noted one serious event in part A and 17 events across parts A and B combined, but does not provide full event-by-event details.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
